Advantages of Radient Pharmaceuticals' Onko-Sure In Vitro Diagnostic Cancer Test Over CEA Published in Journal of Immunoassay and Immunochemistry
Published: Apr 14, 2010
TUSTIN, CA--(Marketwire - April 14, 2010) - US-based pharmaceutical company Radient Pharmaceuticals Corporation (NYSE Amex: RPC) announced today the Journal of Immunoassay and Immunochemistry (April 2010, Volume 31) has published a peer-reviewed journal article written by Dr. Andrea Small-Howard and Mr. Holden Harris titled "Advantages of the AMDL-ELISA DR-70 (FDP) Assay Over Carcinoembryonic Antigen (CEA) for Monitoring Colorectal Cancer Patients."
The Journal of Immunoassay and Immunochemistry article introduces Onko-Sure, the AMDL-ELISA DR-70 (FDP) test developed by Radient Pharmaceuticals, as the first new in vitro diagnostic (IVD) cancer test to be cleared by the US FDA since January 14, 1982 for monitoring CRC. The article also discusses the importance of colorectal cancer screening and monitoring tools in enhancing survival in post-operative colorectal cancer patients because approximately 50% of all CRC patients treated will experience cancer recurrence. RPC's clinical trial is the first head-to-head comparison assessing the effectiveness of Onko-Sure versus CEA for monitoring CRC recurrence.
The article specifically outlines the advantages of the AMDL-ELISA DR-70 (FDP) test over CEA for monitoring CRC; the tremendous economic and healthcare benefits of routine cancer screening, including the potential to detect CRC in its earliest stages where the disease is the most preventable and/or treatable; and the merits of the AMDL-ELISA DR-70 (FDP) cancer test as a welcome, new option for CRC patients. Data covered includes:
- An overview of the advantages of Radient Pharmaceuticals' AMDL-ELISA DR-70 (FDP) IVD cancer test;
- An overview of the deficiencies of the Carcinoembryonic Antigen blood test;
- Clinical effectiveness comparison of the AMDL-ELISA DR-70 (FDP) test versus CEA in serial samples from 113 biopsy-positive CRC patients during routine CRC monitoring;
- A schematic describing how the AMDL-ELISA DR-70 (FDP) IVD cancer test measures FDP generated from all major cancers; and,
- Details on the advantages of Radient Pharmaceuticals' AMDL-ELISA DR-70 (FDP) test to CEA including data revealing that approximately 50% of CRC patients are CEA negative.
The Journal of Immunoassay & Immunochemistry is an international forum for rapid dissemination of research results and methodologies dealing with all aspects of immunoassay and immunochemistry, as well as selected aspects of immunology. They include receptor assay, enzyme-linked immunosorbent assay (ELISA) in all of its embodiments, ligand-based assays, biological markers of ligand-receptor interaction, in vivo and in vitro diagnostic reagents and techniques, diagnosis of AIDS, point-of-care testing, clinical immunology, antibody isolation and purification, and others.
RPC's Onko-Sure (AMDL-ELISA DR-70 FDP) IVD Cancer Test
Onko-Sure is a simple, non-invasive, patent-pending and regulatory-approved cancer test. For tested patients, Onko-Sure™ measures the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP) -- products that are often underestimated by other tests.
To obtain a copy of the "Advantages of the AMDL-ELISA DR-70 (FDP) Assay over Carcinoembryonic Antigen (CEA) for Monitoring Colorectal Cancer Patients" article please visit http://www.radient-pharma.com. For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company's corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at kszarkowitz@Radient-Pharma.com or 1.206.310.5323.
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, and premium skin care products.
Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.